The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC).
Hui Zhu
No relevant relationships to disclose
Andria Valeria Arrossi
No relevant relationships to disclose
Paul Elson
No relevant relationships to disclose
Carol Farver
No relevant relationships to disclose
Raymond R. Tubbs
No relevant relationships to disclose
Sudish C. Murthy
No relevant relationships to disclose
David P. Mason
No relevant relationships to disclose
Peter J. Mazzone
No relevant relationships to disclose
Nathan A. Pennell
Consultant or Advisory Role - Oncogenex; Teva